Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial
Authors not listed
Otsuka Pharmaceutical Development & Commercialization, Inc. · 2014
Abstract
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Anonymous. (2014). A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial. <em>Otsuka Pharmaceutical Development & Commercialization, Inc.</em>. https://clinicaltrials.gov/study/NCT02192554
Vancouver
Anonymous. A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial. Otsuka Pharmaceutical Development & Commercialization, Inc.. 2014.
BibTeX
@misc{anon2014AMonth,
title = {A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial},
author = {Anonymous},
journal = {Otsuka Pharmaceutical Development & Commercialization, Inc.},
year = {2014},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nature Reviews Molecular Cell Biology 2023
Preprint · OA
FOXO transcription factors as mediators of stress adaptation
Otsuka Pharmaceutical Development & Commercialization, Inc. 2020
Open access · US-GOV
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Developmental Biology 2010
Open access · OA
Functional divergence of dafachronic acid pathways in the control of C. elegans development and lifespan
Springer eBooks 2015
Citation only
Genes and Pathways That Influence Longevity in Caenorhabditis elegans
Nature Genetics 2007
Citation only
DAF-16/FOXO targets genes that regulate tumor growth in Caenorhabditis elegans
Neurology Office of South Florida 2025
Open access · US-GOV